OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Cancer Journal is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Disparities in time to treatment with oral antimyeloma medications	361
BCR::ABL1-positive acute lymphoblastic leukemia as a high-risk feature of central nervous system relapse after allogeneic hematopoietic cell transplantation	166
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report	152
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes	105
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	102
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	96
Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience	93
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study	93
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	91
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma	84
A multiparametric niche-like drug screening platform in acute myeloid leukemia	83
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M	72
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease	71
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency	68
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL	66
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma	63
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	61
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma	59
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid	56
Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort	54
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	53
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma	53
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity	53
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study	52
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes	51

Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study	51
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	51
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients	51
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management	50
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma	49
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significa	48
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier	48
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia	48
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression	48
Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database	45
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment	45
Molecular variants, clonal evolution and clinical relevance in pediatric and adult T-cell lymphoblastic neoplasia	43
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia	43
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome	43
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review	42
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia	42
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma	41